Immatics (IMTX) Share-based Compensation (2019 - 2025)
Immatics recorded quarterly Share-based Compensation of $3.8 million in Q4 2025, up 1.48% quarter-over-quarter from $3.8 million in Q3 2025, and down 20.57% year-over-year from $4.8 million in Q4 2024.
Immatics' Share-based Compensation history runs 7 years deep, the most recent figure standing at $3.8 million for Q4 2025.
- In Q4 2025, Share-based Compensation fell 20.57% year-over-year to $3.8 million; the TTM figure through Dec 2025 stood at $16.9 million (down 11.63% YoY), while the FY2025 annual figure was $17.0 million, down 10.02% from the prior year.
- Share-based Compensation came in at $3.8 million for Q4 2025 at Immatics, up from $3.8 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $10.0 million in Q1 2021 to a low of -$17.5 million in Q4 2023.
- A 5-year average of $4.6 million and a median of $5.3 million in 2021 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation surged 23165.37% in 2021 and tumbled 393.7% in 2023, its largest moves.
- Immatics' Share-based Compensation stood at $5.4 million in 2021, then gained by 10.16% to $6.0 million in 2022, then sank by 393.7% to -$17.5 million in 2023, then surged by 127.64% to $4.8 million in 2024, then fell by 20.57% to $3.8 million in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $3.8 million, $3.8 million, and $4.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Immatics | 1.80 Bn | 1.80 Bn | - | 3.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.84 Mn |
| Dec 31, 2025 | 3.84 Mn |
| Sep 30, 2025 | 3.79 Mn |
| Sep 30, 2025 | 3.79 Mn |
| Jun 30, 2025 | 4.69 Mn |
| Jun 30, 2025 | 4.69 Mn |
| Mar 31, 2025 | 4.55 Mn |
| Mar 31, 2025 | 4.55 Mn |
| Dec 31, 2024 | 4.84 Mn |
| Dec 31, 2024 | 4.84 Mn |
| Sep 30, 2024 | 4.95 Mn |
| Sep 30, 2024 | 4.95 Mn |
| Jun 30, 2024 | 4.64 Mn |
| Jun 30, 2024 | 4.64 Mn |
| Mar 31, 2024 | 4.67 Mn |
| Mar 31, 2024 | 4.67 Mn |
| Dec 31, 2023 | -17.51 Mn |
| Dec 31, 2023 | -17.51 Mn |
| Sep 30, 2023 | 5.10 Mn |
| Sep 30, 2023 | 5.10 Mn |
| Jun 30, 2023 | 6.00 Mn |
| Jun 30, 2023 | 6.00 Mn |
| Mar 31, 2023 | 6.55 Mn |
| Mar 31, 2023 | 6.55 Mn |
| Dec 31, 2022 | 5.96 Mn |
| Dec 31, 2022 | 5.96 Mn |
| Sep 30, 2022 | 5.51 Mn |
| Sep 30, 2022 | 5.51 Mn |
| Jun 30, 2022 | 5.93 Mn |
| Jun 30, 2022 | 5.93 Mn |
| Mar 31, 2022 | 6.40 Mn |
| Mar 31, 2022 | 6.40 Mn |
| Dec 31, 2021 | 5.41 Mn |
| Dec 31, 2021 | 5.41 Mn |
| Sep 30, 2021 | 6.37 Mn |
| Sep 30, 2021 | 6.37 Mn |
| Jun 30, 2021 | 9.59 Mn |
| Jun 30, 2021 | 9.59 Mn |
| Mar 31, 2021 | 10.02 Mn |
| Mar 31, 2021 | 10.02 Mn |
| Dec 31, 2020 | -182.11 Mn |
| Dec 31, 2020 | -182.11 Mn |
| Sep 30, 2020 | -178.47 Mn |
| Sep 30, 2020 | -178.47 Mn |
| Jun 30, 2020 | 7.59 Mn |
| Jun 30, 2020 | 7.59 Mn |
| Mar 31, 2020 | 43,053.62 |
| Mar 31, 2020 | 43,053.62 |
| Dec 31, 2019 | 39,847.96 |
| Dec 31, 2019 | 39,847.96 |
| Sep 30, 2019 | 41,171.01 |
| Sep 30, 2019 | 41,171.01 |